The past and future of haemophilia

diagnosis, treatments, and its complications

Flora Peyvandi, Isabella Garagiola, Guy Young

Research output: Contribution to journalReview article

101 Citations (Scopus)

Abstract

Haemophilia A and B are hereditary haemorrhagic disorders characterised by deficiency or dysfunction of coagulation protein factors VIII and IX, respectively. Recurrent joint and muscle bleeds lead to severe and progressive musculoskeletal damage. Existing treatment relies on replacement therapy with clotting factors, either at the time of bleeding (ie, on demand) or as part of a prophylactic schedule. The major complication of such therapy is the development of neutralising antibodies (ie, inhibitors), which is most frequent in haemophilia A. Treatment might improve considerably with the availability of new modified drugs, which might overcome existing prophylaxis limitations by reducing dosing frequency and thereby rendering therapy less distressing for the patient. Subcutaneous administration of some new therapies would also simplify prophylaxis in children with poor venous access. Gene therapy has the potential for a definitive cure, and important results have been obtained in haemophilia B. Despite improvements in haemophilia care, the availability of clotting factor concentrates for all affected individuals worldwide remains the biggest challenge.

Original languageEnglish
Pages (from-to)187-197
Number of pages11
JournalThe Lancet
Volume388
Issue number10040
DOIs
Publication statusPublished - Jul 9 2016

Fingerprint

Hemophilia A
Hemophilia B
Blood Coagulation Factors
Therapeutics
Hemorrhagic Disorders
Factor IX
Bleeding Time
Factor VIII
Neutralizing Antibodies
Genetic Therapy
Appointments and Schedules
Joints
Muscles
Pharmaceutical Preparations
Proteins

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The past and future of haemophilia : diagnosis, treatments, and its complications. / Peyvandi, Flora; Garagiola, Isabella; Young, Guy.

In: The Lancet, Vol. 388, No. 10040, 09.07.2016, p. 187-197.

Research output: Contribution to journalReview article

Peyvandi, Flora ; Garagiola, Isabella ; Young, Guy. / The past and future of haemophilia : diagnosis, treatments, and its complications. In: The Lancet. 2016 ; Vol. 388, No. 10040. pp. 187-197.
@article{e5b49ba11be04ba99c07dbd8f1547238,
title = "The past and future of haemophilia: diagnosis, treatments, and its complications",
abstract = "Haemophilia A and B are hereditary haemorrhagic disorders characterised by deficiency or dysfunction of coagulation protein factors VIII and IX, respectively. Recurrent joint and muscle bleeds lead to severe and progressive musculoskeletal damage. Existing treatment relies on replacement therapy with clotting factors, either at the time of bleeding (ie, on demand) or as part of a prophylactic schedule. The major complication of such therapy is the development of neutralising antibodies (ie, inhibitors), which is most frequent in haemophilia A. Treatment might improve considerably with the availability of new modified drugs, which might overcome existing prophylaxis limitations by reducing dosing frequency and thereby rendering therapy less distressing for the patient. Subcutaneous administration of some new therapies would also simplify prophylaxis in children with poor venous access. Gene therapy has the potential for a definitive cure, and important results have been obtained in haemophilia B. Despite improvements in haemophilia care, the availability of clotting factor concentrates for all affected individuals worldwide remains the biggest challenge.",
author = "Flora Peyvandi and Isabella Garagiola and Guy Young",
year = "2016",
month = "7",
day = "9",
doi = "10.1016/S0140-6736(15)01123-X",
language = "English",
volume = "388",
pages = "187--197",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Lancet Publishing Group",
number = "10040",

}

TY - JOUR

T1 - The past and future of haemophilia

T2 - diagnosis, treatments, and its complications

AU - Peyvandi, Flora

AU - Garagiola, Isabella

AU - Young, Guy

PY - 2016/7/9

Y1 - 2016/7/9

N2 - Haemophilia A and B are hereditary haemorrhagic disorders characterised by deficiency or dysfunction of coagulation protein factors VIII and IX, respectively. Recurrent joint and muscle bleeds lead to severe and progressive musculoskeletal damage. Existing treatment relies on replacement therapy with clotting factors, either at the time of bleeding (ie, on demand) or as part of a prophylactic schedule. The major complication of such therapy is the development of neutralising antibodies (ie, inhibitors), which is most frequent in haemophilia A. Treatment might improve considerably with the availability of new modified drugs, which might overcome existing prophylaxis limitations by reducing dosing frequency and thereby rendering therapy less distressing for the patient. Subcutaneous administration of some new therapies would also simplify prophylaxis in children with poor venous access. Gene therapy has the potential for a definitive cure, and important results have been obtained in haemophilia B. Despite improvements in haemophilia care, the availability of clotting factor concentrates for all affected individuals worldwide remains the biggest challenge.

AB - Haemophilia A and B are hereditary haemorrhagic disorders characterised by deficiency or dysfunction of coagulation protein factors VIII and IX, respectively. Recurrent joint and muscle bleeds lead to severe and progressive musculoskeletal damage. Existing treatment relies on replacement therapy with clotting factors, either at the time of bleeding (ie, on demand) or as part of a prophylactic schedule. The major complication of such therapy is the development of neutralising antibodies (ie, inhibitors), which is most frequent in haemophilia A. Treatment might improve considerably with the availability of new modified drugs, which might overcome existing prophylaxis limitations by reducing dosing frequency and thereby rendering therapy less distressing for the patient. Subcutaneous administration of some new therapies would also simplify prophylaxis in children with poor venous access. Gene therapy has the potential for a definitive cure, and important results have been obtained in haemophilia B. Despite improvements in haemophilia care, the availability of clotting factor concentrates for all affected individuals worldwide remains the biggest challenge.

UR - http://www.scopus.com/inward/record.url?scp=84982855886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982855886&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(15)01123-X

DO - 10.1016/S0140-6736(15)01123-X

M3 - Review article

VL - 388

SP - 187

EP - 197

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 10040

ER -